Two AIQ-Sponsored Abstracts Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2023

July 19, 2023 – Mikaela Dell’Oro, AIQ Solutions Research Collaborator and Research Scientist at University of Western Australia, received acceptance for two poster presentations at the European Society for Medical Oncology (ESMO) Congress 2023. We are proud to showcase our latest work at one of the most influential oncology platforms for clinicians, researchers, patient advocates, journalists, and healthcare industry representatives from around the world. AIQ also presented at the ESMO Congress in 2019 and two posters in 2022. ESMO Congress 2023 will take place in Madrid, Spain from 20 to 24 October 2023.

To learn more, (click here).

AIQ Solutions is Proud Recipient of Phase 2 SBIR Advance Programs

May 30, 2023 – AIQ Solutions is among ten companies receiving up to $850,000 to commercialize their innovations through the Small Business Innovation Research (SBIR) Advance Program. Supported by the Wisconsin Economic Development Corporation (WEDC), SBIR Advance matches up to $100,000 of federal grant dollars. AIQ qualified for the matching grant after being awarded their second of two years of a $2M grant from the National Institutes of Health. Additionally, AIQ will receive mentorship and training from the Wisconsin Center for Technology Commercialization.

Read the full news (here).

About the Center for Technology Commercialization

The Center for Technology Commercialization provides one-on-one assistance to early-stage emerging technology businesses throughout Wisconsin. From agriculture to biotechnology, Center consultants are experts in commercialization processes.

To learn more, (click here).

Dr. Timothy Perk Invited as Keynote Speaker at Webinar hosted by OneMedNet

May 15, 2023 – Dr. Tim Perk, VP of Research from AIQ Solutions will be joining a webinar hosted by OneMedNet focused on the use of real-world data (RWD) to optimize TRAQinform IQ technology for prostate cancer.  Recent approval of prostate specific membrane antigen (PSMA) theranostic is rapidly changing the standard of care for diagnosing, staging and managing prostate cancer.  Key challenges exist with theranostics such as identifying which patients would benefit from treatment, optimizing the therapeutic dose, monitoring and predicting treatment response, and preventing toxicity.

Key Learnings:

  • How to define, identify and recruit the metastatic castration-resistant prostate cancer (mCRPC) patient cohort required to assess PSMA’s role in prostate cancer
  • Leveraging imaging RWD to assess the mCRPC PET Scan
  • Learning about a new technology, TRAQinform IQ, that will use standard-of-care imaging to support clinical decisions around the use of theranostics
  • Understanding how TRAQinform IQ technology will be used for theranostics treatment optimization

Contact AIQ Solutions to be directed to this webinar recording and visit AIQ webinars for access to the entire library of webinars by AIQ Solutions.

About OneMedNet

OneMedNet provides high-quality, insight rich data to Life Science organizations for immediate use in Discovery, Development, Regulatory Approval, and Post-Market Surveillance.

To learn more, (click here).

AIQ Solutions Will Host Symposium at the 2023 Australia and New Zealand Society for Nuclear Medicine (ANZSNM) Annual Meeting

May 10, 2023 – AIQ will host an Industry Symposium Breakfast Session at the 2023 Australia and New Zealand Society for Nuclear Medicine (ANZSNM) annual scientific meeting in Adelaide, South Australia on the 26-28th May 2023. Professors Dale Bailey, Principal Physicist at Royal North Shore Hospital and Roslyn Francis, Associate Professor of Molecular Imaging at The University of Western Australia discussed “Does imaging hold the key to better outcomes in theranostics?”. AIQ CEO, Eric Horler, will join them to talk about “Novel Al-based technology for optimizing theranostics decision making.”


Since 1969, ANZSNM has been the professional society for people working across all areas of professional practice in nuclear medicine across Australia and New Zealand.

To learn more, (click here).

AIQ Solutions Will Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

April 24, 2023 – AIQ’s collaboration with researchers at Rocky Mountain Cancer Center will be highlighted in an oral presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in Chicago, June 24-27.

The abstract title is Cross-radiotracer generalizability of automated lesion detection via CNN: pilot study in 64Cu- and 68Ga-DOTATATE PET/CT. AIQ Research Scientist, Ojaswita Lokre will be presenting on Tuesday June 27, 3:30pm CT.

To request a copy of the presentation, (click here).


The Society of Nuclear Medicine and Molecular Imaging (SNMMI), headquartered in Reston, Va., is a nonprofit scientific and professional organization that promotes the science, technology and practical application of nuclear medicine and molecular imaging.

To learn more, (click here).

AIQ Solutions Named One of the Best Tech Startups in Madison

March 24, 2023 – AIQ Solutions was selected by The Tech Tribune as one of the best tech startups in Madison, Wisconsin. This designation is based on revenue potential, leadership team, brand/product traction, competitive landscape, and other factors.

To learn more, (click here).

About The Tech Tribune

Founded in 2017, The Tech Tribune delivers the latest technology news, in-depth technology articles, exclusive interviews with entrepreneurs, and insights on the hottest technology startups all over the world.

AIQ Solutions is Registered Supplier on

March 08, 2023 – AIQ Solutions joined, the world’s largest digital marketplace for medical research supporting companies to accelerate therapy and radiotracer development. Among their suppliers, the biomarker supplier community offers a wide range of services. AIQ’s software technology complements the community by enabling research scientists to better understand treatment response heterogeneity and toxicity risk by analyzing radiological imaging scans.

Joining the supplier community allows AIQ to provide timely proposals and streamline ordering processes for their clients. (Click here) to view AIQ’s profile and offerings available on

AIQ Co-Founder and Chief Technology Officer, Guy Starbuck, Interviewed by News Medical

February 14, 2023 – During the Society for Laboratory Automation and Screening (SLAS) international conference and exhibition, News Medical interviewed Guy Starbuck, AIQ Solutions Co-Founder and CTO. Guy provided his insights about how AI technology can be utilized to bring new medical devices to market. During this interview, Guy shared the current challenges of treating cancer, especially late-stage disease because each lesion can respond differently to treatment (response heterogeneity). He explained how AIQ technologies provide critical intelligence to oncologists supporting more confident treatment decisions.

Read the full interview (here).

About News Medical

News Medical is one of the world’s leading open-access medical and life science hubs. They were designed to put medical and life sciences information in reach of people that can make a difference. Healthcare professionals, researchers, and engaged consumers can access a wealth of open-access content from thought leaders across the world.

To learn more, (click here).

AIQ Technology Now Detects and Segments Lesions, Quantifies Lesion-Wise Response and Heterogeneity on CT Images

January 17, 2023 – In AIQ’s latest white paper, several studies demonstrate the ability of AIQ technology to detect and segment lesions and quantify lesion-wise change over time on diagnostic CT images with or without contrast-enhancement. This allows wider access of AIQ’s technology in the medical community to quantitatively evaluate all of a patient’s disease throughout care using standard of care diagnostic CT images.

Access the white paper (here).

Timothy Perk Ph.D. Promoted to Vice President of Research

January 02, 2023 – AIQ is pleased to announce that Timothy Perk, Ph.D. was promoted to Vice President of Research. Dr. Perk is an expert in advanced image and statistical analysis methods focused on developing novel techniques to quantitatively assess medical images. He will continue to provide strategic leadership, direct a team of research scientists, manage external research collaborations, and design and implement scalable technical solutions for AIQ’s innovative products, including development of new algorithms, making improvements to process automation, and enhancing the accuracy and performance of software components. He is a co-inventor of AIQ’s foundational technology, licensed from the University of Wisconsin. Prior to this position he served as a consultant with AIQ Solutions, advising on FDA 510(k) clearance process of their software and reviewed documents and performing quality control of image analysis.

Before his transition to industry, Dr. Perk was a Research Associate with Dr. Robert Jeraj at the University of Wisconsin. During this time, he served as Data Security officer for the Wisconsin Oncology Network for Imaging Excellence (WONIX), assisted in building the Networks for Imaging Excellence (NIX) alliance, an international alliance established for the purpose of accelerating research in quantitative imaging in medicine, and served as manager of the Image analysis core (IMAC).

To learn more about the AIQ Solutions Leadership Team, (click here).

Successful Completion of Medical Device Single Audit Program (MDSAP)

October 26, 2022 – AIQ is pleased to announce a successful completion of Medical Device Single Audit Program (MDSAP) certification and ISO-13485:2016 audits.

This certification validates our ongoing commitment to the highest quality assurance standards within the medical device industry as required by regulatory authorities across the world. MDSAP certification is a significant and necessary step on the path to international expansion. MDSAP certification is valid for 3 years.

To learn more, (click here).

More >>

Australian Privacy Policy AIQ's software has been cleared for clinical use under 510(k) K173444. For details, including the applicable Indications for Use, see: